Tafoxiparin Dosing for Spontaneous Labor Without Prostaglandin Risks
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for inducing labor in term pregnant women, particularly those with an unripe cervix, often involve invasive procedures or pharmaceutical interventions that can have side effects, and there is a need for a safer and more effective method to initiate spontaneous labor.
Innovation Solution
The use of tafoxiparin, a chemically modified heparin derivative with specific molecular characteristics, as a monotherapy to induce spontaneous labor in term pregnant women, administered in doses ranging from 30-320 mg daily, targeting the uterine tissue to facilitate cervical ripening and labor onset.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If prostaglandins (PGE2 or PGE1) are administered locally to induce labor, then cervical ripening is achieved, but side effects occur including hypercontractility and bad influence on umbilical blood flow
Solution Approach 1:
The patent modifies the chemical structure of heparin to create tafoxiparin with specific molecular characteristics (molecular weight 4.6-6.9 kDa, specific sulfation pattern) that change its biological parameters to achieve cervical ripening without the harmful side effects of prostaglandins
Solution Approach 2:
Tafoxiparin acts as an intermediary substance that mediates cervical ripening through its interaction with cervical tissue, providing the beneficial effect of cervical softening and dilation without directly causing the harmful hypercontractility associated with prostaglandins
2Productivity
If oxytocin is administered intravenously to induce labor, then uterine contractions are potentiated, but the method requires continuous monitoring and controlled administration
Solution Approach 1:
The patent replaces the mechanical intravenous infusion system with a simpler subcutaneous injection method, eliminating the need for continuous monitoring and controlled administration while maintaining labor induction effectiveness
Solution Approach 2:
Tafoxiparin is designed to be self-regulating in its action, providing sustained cervical ripening and labor induction without requiring external control mechanisms, monitoring systems, or adjusted administration protocols
3Productivity
If amniotomy is performed to induce labor, then labor can be initiated, but it requires invasive procedures and carries risks
Solution Approach 1:
Tafoxiparin performs preliminary cervical ripening action before labor initiation, softening and preparing the cervix in advance, which then enables spontaneous labor onset without requiring invasive amniotomy procedures
Solution Approach 2:
The patent converts the potential harm of requiring invasive procedures into a benefit by using tafoxiparin to achieve cervical ripening through a non-invasive mechanism, thereby eliminating the need for amniotomy and its associated risks
4Reliability
If cervical balloon is used to ripen the cervix, then labor induction is achieved, but it requires invasive placement and removal procedures
Solution Approach 1:
The patent replaces the mechanical balloon catheter system with a pharmacological solution (tafoxiparin) that achieves cervical ripening through chemical action, eliminating the need for invasive placement and removal procedures
Data Source
AI summary
The present invention is directed to tafoxiparin for use in the spontaneous onset of labor in a term pregnant woman. wherein tafoxiparin is administered in a daily dose of 30-320 mg per day.